All Stories

  1. Systematic cascade screening in the Danish Fabry Disease Centre: 20 years of a national single-centre experience
  2. Significant hearing loss in Fabry disease: Study of the Danish nationwide cohort prior to treatment
  3. Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997–2013: a nationwide study
  4. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis
  5. Corrigendum to “Challenges in Interpretation of Thyroid Function Tests in Pregnant Women with Autoimmune Thyroid Disease”
  6. Adrenal Insufficiency Caused by Locally Applied Glucocorticoids-Myth or Fact?
  7. Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
  8. Early endocrine alterations reflect prolonged stress and relate to 1-year functional outcome in patients with severe brain injury
  9. Quality of Life in Patients with Benign Nontoxic Goiter: Impact of Disease and Treatment Response, and Comparison with the General Population
  10. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges
  11. Thyroid-specific questions on work ability showed known-groups validity among Danes with thyroid diseases
  12. Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement
  13. Claus Brun (1914-2014)
  14. Primary Hyperparathyroidism in Young People. When Should We Perform Genetic Testing for Multiple Endocrine Neoplasia 1 (MEN-1)?
  15. Exploring the Experiences of People With Hypo- and Hyperthyroidism
  16. Corrigendum to “Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself” [Eur J Intern Med, 24 (8), 714–720]
  17. The Thyroid-Related Quality of Life Measure ThyPRO Has Good Responsiveness and Ability to Detect Relevant Treatment Effects
  18. OR7-1: A reversible albumin-binding GH derivative possesses a promising once-weekly treatment profile and is well tolerated in adult subjects with growth hormone deficiency
  19. PO2-11: Evidence for truncated somatostatin receptor 5 modulation of therapy response to somatostatin analogues in two patients with acromegaly and severe headache
  20. Confirmatory factor analysis of the thyroid-related quality of life questionnaire ThyPRO
  21. Cross-cultural validity of the thyroid-specific quality-of-life patient-reported outcome measure, ThyPRO
  22. Increased Risk of Long-Term Sickness Absence, Lower Rate of Return to Work, and Higher Risk of Unemployment and Disability Pensioning for Thyroid Patients: A Danish Register-Based Cohort Study
  23. Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma
  24. Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis
  25. Incidence and late prognosis of acromegaly in Denmark: preliminary data
  26. Prolactin hyperproduction does not predict the risk of glucose metabolic disturbances in patients with acromegaly
  27. Glucocorticoid-induced adrenal insufficiency in prednisolone treated patients and how it relates to glucocorticoid dose and the duration of treatment
  28. Di-ethylhexyl-phthalate is metabolised by human thyroid cells and may influence thyroglobulin secretion
  29. Evidence for truncated somatostatin receptor 5 modulation of therapy response to somatostatin analogues in two patients with acromegaly and severe headache
  30. DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper
  31. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial
  32. Sleep-wake and melatonin pattern in craniopharyngioma patients
  33. Development and implementation of PROgmatic: A clinical trial management system for pragmatic multi-centre trials, optimised for electronic data capture and patient-reported outcomes
  34. Female Fabry disease: significant improvement of Fabry disease-related gastrointestinal symptoms in a large cohort of female patients treated with agalsidase beta: data from the Fabry Registry
  35. Myxoedema coma: an almost forgotten, yet still existing cause of multiorgan failure
  36. Anxiety and Depression Are More Prevalent in Patients with Graves' Disease than in Patients with Nodular Goitre
  37. Prevalence of Posttraumatic Growth Hormone Deficiency Is Highly Dependent on the Diagnostic Set-up: Results From The Danish National Study on Posttraumatic Hypopituitarism
  38. Faculty of 1000 evaluation for Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: A randomized controlled clinical trial.
  39. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself
  40. Gestational age-specific reference ranges from different laboratories misclassify pregnant women's thyroid status: comparison of two longitudinal prospective cohort studies
  41. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease
  42. Faculty of 1000 evaluation for A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
  43. Faculty of 1000 evaluation for Effectiveness of an oxidized cellulose patch hemostatic agent in thyroid surgery: a prospective, randomized, controlled study.
  44. Faculty of 1000 evaluation for Neural correlates of free T3 alteration after catecholamine depletion in subjects with remitted major depressive disorder and in controls.
  45. Faculty of 1000 evaluation for Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis.
  46. Massive prolactinoma in women: a study of 15 cases
  47. Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement
  48. Central Hypothyroidism and Its Replacement Have a Significant Influence on Cardiovascular Risk Factors in Adult Hypopituitary Patients
  49. Faculty of 1000 evaluation for Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy.
  50. Faculty of 1000 evaluation for Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.
  51. Faculty of 1000 evaluation for Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma.
  52. Few items in the thyroid-related quality of life instrument ThyPRO exhibited differential item functioning
  53. Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly
  54. Differential item functioning of the thyroid-specific quality of life questionnaire ThyPRO
  55. Hypopituitarism after fractionated stereotactic radiation therapy of anterior skull base meningiomas is caused by mass effects, not radiation
  56. Relationship between early endocrine alterations and functional outcome in patients with severe brain injury
  57. The characterization of sleep--wake pattern and its association with melatonin, as a marker of the circadian function of the suprachiasmatic nucleus, in craniopharyngioma patients
  58. The prevalence of insufficient test responses in patients with traumatic brain injury compared to healthy controls -- results from The Danish National Study on posttraumatic hypopituitarism
  59. Response to GH treatment in adult GH deficiency is predicted by gender, age, and IGF1 SDS but not by stimulated GH-peak
  60. Careful Assessment of Maternal Thyroid Function Can Prevent Cases of Fetal Goitrous Hypothyroidism
  61. Selenium supplementation for patients with Graves� hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial
  62. Results and summary of voting among the audience during presentation and discussion of Medullary Thyroid Carcinoma clinical guidelines prepared by American Thyroid Association
  63. Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves’ disease
  64. Acute presentation of craniopharyngioma in children and adults in a Danish national cohort
  65. Further Thoughts on the Diagnosis and Diagnostic Criteria for Thyroid Storm
  66. P01-50 Smoking, body composition and bone health in adult patients with Growth Hormone (GH)-treated GH deficiency – an observational study
  67. P03-39 Cross-sectional studies are prone to selection bias; example from the Danish national study on posttraumatic hypopituitarism
  68. Fabry disease in children: agalsidase-beta enzyme replacement therapy
  69. Mannose 6-Phosphate Receptor and Sortilin Mediated Endocytosis of α-Galactosidase A in Kidney Endothelial Cells
  70. Thyroid effects of endocrine disrupting chemicals
  71. Similar Clinical Features Among Patients with Severe Adult Growth Hormone Deficiency Diagnosed with Insulin Tolerance Test or Arginine or Glucagon Stimulation Tests
  72. Endocrinology
  73. P20—Agalsidase Beta Treatment is Associated With Improvement in Quality of Life in Patients With Fabry Disease: Findings From the Fabry Registry
  74. P27—Uptake of α-Galactosidase a in Human Glomerular Podocytes is Mediated by Various Receptors in Fabry Disease
  75. Overall and cause-specific mortality in GH-deficient adults on GH replacement
  76. Thyroid cancer in Denmark 1943-2008, before and after iodine supplementation
  77. The Case of Hypopituitarism in Traumatic Brain Injury
  78. Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry Registry
  79. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood
  80. Neuroendocrine Monitoring
  81. Neuroendocrine Treatment
  82. Is Thyroid Autoimmunity per se a Determinant of Quality of Life in Patients with Autoimmune Hypothyroidism?
  83. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage
  84. Endocrine disorders in pregnancy: Physiological and hormonal aspects of pregnancy
  85. Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association
  86. Diagnostic dilemma: A young woman with Fabry disease symptoms, no family history, and a “sequencing cryptic” α-galactosidase a large deletion
  87. The metabolic consequences of thyroxine replacement in adult hypopituitary patients
  88. Receptor-Mediated Endocytosis of α-Galactosidase A in Human Podocytes in Fabry Disease
  89. The Benefits of Invasive Treatment of Fetal Goitrous Hypothyroidism in Maternal Graves' Disease
  90. Escitalopram and Neuroendocrine Response in Healthy First-Degree Relatives to Depressed Patients – A Randomized Placebo-Controlled Trial
  91. Faculty Opinions recommendation of Selenium and the course of mild Graves' orbitopathy.
  92. Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1β and inhibited by growth hormone releasing hormone and somatostatin
  93. Comment on “intrauterine diagnosis and management of fetal goiter: A case report”
  94. Antithyroid drug induced fetal goiter
  95. Pegylated Long-Acting Human Growth Hormone Possesses a Promising Once-Weekly Treatment Profile, and Multiple Dosing Is Well Tolerated in Adult Patients with Growth Hormone Deficiency
  96. Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults
  97. Graves' Disease in Pregnancies Complicated by Fetal Goitrous Hypothyroidism in Utero T4 treatment
  98. Lessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY
  99. Challenges in Interpretation of Thyroid Function Tests in Pregnant Women with Autoimmune Thyroid Disease
  100. Do Thyroid Disrupting Chemicals Influence Foetal Development during Pregnancy?
  101. Fabry Disease and Early Stroke
  102. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
  103. GH and IGF1 levels are positively associated with musculotendinous collagen expression: experiments in acromegalic and GH deficiency patients
  104. Childhood Exposure to Phthalates: Associations with Thyroid Function, Insulin-like Growth Factor I, and Growth
  105. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women
  106. Autoimmunity in differentiated thyroid cancer: Significance and related clinical problems
  107. Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit
  108. Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease
  109. Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves' disease?
  110. Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage
  111. P18 Baseline characteristics and quality of life in patients with childhood-onset growth hormone deficiency due to Cushing's disease and non-functioning pituitary adenoma
  112. OR7,39 GH responsiveness in hypopituitary patients with very severe adult GHD using insulin, arginine or glucagon stimulation tests is associated with IGF-I SDS but not with the stimulated GH peak
  113. Faculty Opinions recommendation of Autoimmune thyroid disease in children and adolescents with idiopathic pulmonary arterial hypertension.
  114. Cardiovascular and Cerebrovascular Events in Temporal Relationship to Intravenous Glucocorticoid Pulse Therapy in Patients with Severe Endocrine Ophthalmopathy
  115. Environmental chemicals and thyroid function: an update
  116. Association of Thyroid Gland Volume, Serum Insulin-Like Growth Factor-I, and Anthropometric Variables in Euthyroid Prepubertal Children
  117. Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO
  118. Narrow intra-individual variation of maternal thyroid function in pregnancy based on a longitudinal study on 132 women
  119. Radioiodine treatment for non-toxic goitre
  120. Functional and structural nerve fiber findings in heterozygote patients with Fabry disease
  121. Autonomic skin responses in females with Fabry disease
  122. COMPARISON BETWEEN HOMOGENEOUS PHASE RADIO-ASSAY AND ENZYME-LINKED IMMUNOSORBENT ASSAY FOR MEASUREMENT OF ANTITHYROGLOBULIN ANTIBODY CONTENT IN SERUM
  123. AUTOREACTIVE LYMPHOCYTES IN THYROID DISORDERS
  124. From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum - a KIMS analysis
  125. Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: the effect of escitalopram vers...
  126. P1.10 Autonomic control of heart rate and blood pressure in Anderson–Fabry's disease
  127. Hypothyroidism is associated with signs of endothelial dysfunction despite 1-year replacement therapy with levothyroxine
  128. Is increase in bone mineral content caused by increase in skeletal muscle mass/strength in adult patients with GH-treated GH deficiency? A systematic literature analysis
  129. Propranolol in the Treatment of Thyrotoxicosis
  130. Establishing construct validity for the thyroid-specific patient reported outcome measure (ThyPRO): an initial examination
  131. Kinetic Models for Plasma Disappearance of Insulin in Normal Subjects
  132. Iodine and tri-iodo-thyronine reduce the incidence of type 1 diabetes mellitus in the autoimmune prone BB rats
  133. Autoantibodies, immune complexes and HLA-D in thyrogastric autoimmunity
  134. HLA-D in Hashimoto's thyroiditis
  135. Faculty Opinions recommendation of Serum concentrations of adiponectin in patients with hyperthyroidism before and after control of thyroid function.
  136. Elevated third-trimester haemoglobin A1c predicts preterm delivery in type 1 diabetes
  137. P-20 Growth hormone treatment in patients on hemodialysis is associated with an increase in serum mannose-binding lectin levels
  138. GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables
  139. Reduced Parietooccipital White Matter Glutamine Measured by Proton Magnetic Resonance Spectroscopy in Treated Graves’ Disease Patients
  140. Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing
  141. Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease
  142. Improving a newly developed patient-reported outcome for thyroid patients, using cognitive interviewing
  143. Immunohistochemical staining for thyroid peroxidase (TPO) of needle core biopsies in the diagnosis of scintigraphically cold thyroid nodules
  144. Faculty Opinions recommendation of Papillary carcinoma of the thyroid gland in a child of thyrotoxicosis patient receiving radioactive iodine therapy: report of a case.
  145. Faculty Opinions recommendation of Endocrine disruptors and the thyroid gland--a combined in vitro and in vivo analysis of potential new biomarkers.
  146. Does the type and severity of brain injury predict hypothalamo–pituitary dysfunction? Does post-traumatic hypopituitarism predict worse outcome?
  147. Morbidity and GH deficiency: a nationwide study.
  148. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
  149. Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density
  150. Interactions Between Growth Hormone and the Thyroid Gland - with Special Reference to Biochemical Diagnosis
  151. Posttraumatic Hypopituitarism Is Associated with an Unfavorable Body Composition and Lipid Profile, and Decreased Quality of Life 12 Months after Injury
  152. Faculty Opinions recommendation of Thyroid autoimmunity and thyroid dysfunction in women with endometriosis.
  153. Signs of maternal vascular dysfunction precede preeclampsia in women with type 1 diabetes
  154. Prevalence and predictive factors of post-traumatic hypopituitarism
  155. Mortality and GH deficiency: a nationwide study
  156. Treatment of Hypothyroidism in Elderly Patients and in Patients with Cardiac Disease
  157. Which Domains of Thyroid-Related Quality of Life Are Most Relevant? Patients and Clinicians Provide Complementary Perspectives
  158. Clinical Implications of Residual Growth Hormone (GH) Response to Provocative Testing in Adults with Severe GH Deficiency
  159. Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study
  160. 285 ABNORMALITIES IN SMALL FIBRE STRUCTURE AND FUNCTION IN FEMALE FABRY PATIENTS
  161. Faculty Opinions recommendation of Thiazolidinedione induced thyroid associated orbitopathy.
  162. Faculty Opinions recommendation of Clinical and subclinical autoimmune thyroid disorders in systemic sclerosis.
  163. Thyroid and Leptin
  164. Factors Influencing the Adrenocorticotropin Test: Role of Contemporary Cortisol Assays, Body Composition, and Oral Contraceptive Agents
  165. Faculty Opinions recommendation of Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery.
  166. Distribution of α-Galactosidase A in Normal Human Kidney and Renal Accumulation and Distribution of Recombinant α-Galactosidase A in Fabry Mice
  167. Relationship between genotype and phenotype in 26 Danish patients with Fabry disease
  168. Serum thyroglobulin as a marker of thyroid neoplasms after childhood cancer
  169. Metabolic Effects of Growth Hormone
  170. Affective symptoms and cognitive functions in the acute phase of Graves’ thyrotoxicosis
  171. Diversity of neuropathy in a familywith Fabry disease
  172. P-62 CHANGES IN LIPID PROFILE IN ADULTS WITH GROWTH HORMONE DEFICIENCY (GHD) AFTER 1 YEAR OF GH REPLACEMENT THERAPY: CORRELATION WITH PARAMETERS OF OBESITY
  173. P-63 RELATIONSHIP BETWEEN GH RESPONSES TO SEVERAL STIMULATION TESTS AND VARIABLES OF LIPID METABOLISM AND BODY COMPOSITION IN ADULT PATIENTS WITH SEVERE GH DEFICIENCY- INSIGHT FROM THE KIMS DATABASE
  174. Is there a need to optimize glycemic control in hemodialyzed diabetic patients?
  175. What is the optimal follow-up strategy for patients with papillary thyroid microcarcinoma?
  176. P3-095
  177. P1-141
  178. Small-fibre neuropathy in female Fabry patients: reduced allodynia and skin blood flow after topical capsaicin
  179. Characteristics of the Danish families with multiple endocrine neoplasia type 1
  180. Growth Hormone Replacement Therapy in Adults: Responsiveness Related to Life Quality
  181. Effect on Muscles of Long-Term Treatment with Growth Hormone (GH) in Adults with GH Deficiency: KIMS Data and Review of the Literature
  182. Pegvisomant Treatment in a 4-Year-Old Girl with Neurofibromatosis Type 1
  183. Serum levels of activin A and inhibin A are not related to the increased susceptibility to pre-eclampsia in type I diabetic pregnancies
  184. Estrogen Replacement in Women of Fertile Years with Hypopituitarism
  185. Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test
  186. Cotreatment of Acromegaly with a Somatostatin Analog and a Growth Hormone Receptor Antagonist
  187. Isolated growth hormone (GH) deficiency in adult patients: Baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database
  188. Estimation of number of follicles, volume of colloid and inner follicular surface area in the thyroid gland of rats
  189. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I
  190. The impact of idiopathic childhood-onset growth hormone deficiency (GHD) on bone mass in subjects without adult GHD
  191. Combined Dietary and Pharmacological Weight Management in Obese Hypopituitary Patients
  192. Impaired health-related quality of life in Graves' disease. A prospective study
  193. Neonatal stimulation of the thyroid gland with iodine or suppression during adolescence with triiodothyronine changes the prevalence of autoimmune thyroiditis in BB rats
  194. Unsuccessful Radioiodine Treatment of a Non-Toxic Goiter: A Case Report
  195. Abnormal bone collagen morphology and decreased bone strength in growth hormone-deficient rats
  196. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults
  197. The insulin-like growth axis in patients with autoimmune thyrotoxicosis: effect of antithyroid drug treatment
  198. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide AutogelR
  199. Effect of Growth Hormone Replacement Therapy on Pituitary Hormone Secretion and Hormone Replacement Therapies in GHD Adults
  200. Obesity: The New Worldwide Epidemic Threat to General Health and Our Complete Lack of Effective Treatment
  201. Thyrotropin-Releasing Hormone Stimulation Test in Patients with Pituitary Pathology
  202. Abnormal Sympathoadrenal Activity, but Normal Energy Expenditure in Hypopituitarism
  203. High Risk of Adrenal Insufficiency in Adults Previously Treated for Idiopathic Childhood Onset Growth Hormone Deficiency
  204. Circulating leptin and thyroid dysfunction
  205. GHD during Critical Phases of Life
  206. Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients Treated with Radiotherapy and Chemotherapy for Childhood Brain Tumor
  207. Ultrasonically measured horizontal eye muscle thickness in thyroid associated orbitopathy: cross-sectional and longitudinal aspects in a Danish series
  208. Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotoxic Graves' disease
  209. Preface
  210. A Population-Based Study of Thyroid Function after Radiotherapy and Chemotherapy for a Childhood Brain Tumor
  211. Comparisons of leptin, incretins and body composition in obese and lean patients with hypopituitarism and healthy individuals
  212. Immune function during GH treatment in GH-deficient adults: an 18-month randomized, placebo-controlled, double-blinded trial
  213. An audit of the insulin-tolerance test in 255 patients with pituitary disease
  214. Fabry disease: a new challenge in endocrinology and metabolism?
  215. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease
  216. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial
  217. The influence of alpha1-acid glycoprotein (orosomucoid) and its glycoforms on the function of human thyrocytes and CHO cells transfected with the human TSH receptor
  218. Cardiac Effects of Low-Dose Growth Hormone Replacement Therapy in Growth Hormone-Deficient Adults
  219. Fabry Disease – A Metabolic Disorder with a Challenge for Endocrinologists?
  220. Long-term Pathologic Changes of α1-Acid Glycoprotein (orosomucoid) Glycoforms in Autoimmune Thyroid Disease
  221. Increased risk of osteoporotic fractures in patients with Cushing's syndrome
  222. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease
  223. Hydrogen peroxide-induced production of a 40 kDa immunoreactive thyroglobulin fragment in human thyroid cells: the onset of thyroid autoimmunity?
  224. Total and free insulin-like growth factor I, insulin-like growth factor binding protein 3 and acid-labile subunit reflect clinical activity in acromegaly
  225. Healthcare Consumption Decreases in Parallel with Improvements in Quality of Life during GH Replacement in Hypopituitary Adults with GH Deficiency
  226. Pregnancy Outcome in Type 1 Diabetic Women With Microalbuminuria
  227. Skin morphological changes in growth hormone deficiency and acromegaly
  228. Thyroid function in survivors of childhood acute lymphoblastic leukaemia: the significance of prophylactic cranial irradiation
  229. Iodine and Cancer
  230. The Influence of Growth Hormone Deficiency, Growth Hormone Replacement Therapy, and Other Aspects of Hypopituitarism on Fracture Rate and Bone Mineral Density
  231. How Should Insulin-Like Growth Factor I Be Measured?
  232. Linomide Does Not Prevent Spontaneous Autoimmune Thyroiditis in NOD Mice
  233. Incidence and Late Prognosis of Cushing’s Syndrome: A Population-Based Study1
  234. Sweat secretion rates in growth hormone disorders
  235. Adrenaline and glycogenolysis in skeletal muscle during exercise: a study in adrenalectomised humans
  236. Growth hormone deficiency and replacement in elderly hypopituitary adults
  237. Thyroperoxidase (TPO) immunostaining of the solitary cold thyroid nodule
  238. (131)I and thyroid-associated ophthalmopathy
  239. Cranial radiotherapy of childhood brain tumours: Growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study
  240. Thyroperoxidase immunostaining in evaluation of thyroid nodules
  241. Can growth hormone therapy cause diabetes?
  242. Free and protein bound leptin are distinct and independently controlled factors in energy regulation
  243. A Case of Sarcoidosis and Sarcoid Granuloma, Papillary Carcinoma, and Graves' Disease in the Thyroid Gland
  244. Thyrocyte-interleukin-1 interactions
  245. Growth Hormone Response to a Growth Hormone-Releasing Hormone Stimulation Test in a Population-Based Study following Cranial Irradiation of Childhood Brain Tumors
  246. Multicenter study on TGPO autoantibody prevalence in various thyroid and non-thyroid diseases; relationships with thyroglobulin and thyroperoxidase autoantibody parameters
  247. The Effects of Treatment and the Individual Responsiveness to Growth Hormone (GH) Replacement Therapy in 665 GH-Deficient Adults
  248. Growth Hormone Replacement Therapy Is Not Associated with Any Increase in Mortality
  249. Effect of adrenaline on glucose kinetics during exercise in adrenalectomised humans
  250. ED4: QUALITY OF LIFE AND USE OF HEALTHCARE RESOURCES IN GROWTH HORMONE-DEFICIENT ADULTS AFTER GROWTH HORMONE REPLACEMENT THERAPY
  251. Co-existence of osteogenesis imperfecta and hyperparathyroidism
  252. Models to study the pathogenesis of thyroid autoimmunity
  253. Lack of Thyroglobulin Production Supports the Finding of the FRTL-5 Cells with a Nondiploid Karyotype
  254. Intestinal Adsorption of Levothyroxine by Antacids and Laxatives: Case Stories andin vitroExperiments
  255. Thyrotropin Stimulates Specifically the Expression of the Autoantibody Binding Domains of the Thyroperoxidase Molecule
  256. Pathogenic and clinical aspects of Graves' disease
  257. The relationship between the serum leptin concentrations of thyrotoxic patients during treatment and their total fat mass is different from that of normal subjects
  258. Efficacy of, and individual susceptibility to, GH-replacement in adults
  259. Regrowth of non-secreting pituitary adenoma and craniopharyngioma prior to GH-replacement therapy in KIMS
  260. Baseline characteristics and diagnosis of GHD in adults with hypopituitarism
  261. Consequences of stopping growthhormone (GH) therapy in young GH deficient patients with childhood onset disease
  262. Inhibition of PTH Secretion by Interleukin-1β in Bovine Parathyroid Glandsin VitroIs Associated with an Up-Regulation of the Calcium-Sensing Receptor mRNA
  263. The Effects of Interleukin-1β (IL-1β) on Human Thyrocyte Functions Are Counteracted by the IL-1 Receptor Antagonist1
  264. Discrepancies between thyrotropin (TSH) measurement by four sensitive immunometric assays
  265. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro.
  266. Interleukin-1  inhibits rat thyroid cell function in vivo and in vitro by an NO-independent mechanism and induces hypothyroidism and accelerated thyroiditis in diabetes-prone BB rats
  267. A direct effect in vitro of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells
  268. Long-Term Observation of Serum Thyroglobulin after Resection of Nontoxic Goiter and Relation to Ultrasonographically Demonstrated Relapse
  269. Thyroid function and autoimmunity in pernicious anemia before and during cyanocobalamin treatment
  270. Diagnosis and treatment of thyrotoxicosis in childhood A European questionnaire study
  271. Bispecific thyroglobulin and thyroperoxidase autoantibodies in patients with various thyroid and autoimmune diseases.
  272. Influence of tumour necrosis factor- , tumour necrosis factor-  and interferon- , separately and added together with interleukin-1  , on the function of cultured human thyroid cells
  273. Riedel's thyroiditis: an autoimmune or primary fibrotic disease?
  274. Nitric Oxide Production is not involved in the Effects of Interleukin-1β on CAMP, Thyroglobulin and Interleukin-6 in TSH-Stimulated Human Thyroid Cells
  275. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease
  276. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.
  277. Reassessment of Antithyroid Drug Therapy of Graves' Disease
  278. Reassessment of Antithyroid Drug Therapy of Graves' Disease
  279. Update: The Effect of Interleukin-1 on the Thyroid Gland
  280. Postpartum Thyroid Dysfunction: Comment
  281. Influence of thyroxine treatment on thyroid size and anti-thyroid peroxidase antibodies in Hashimoto's thyroiditis
  282. Effect of maternal thyroid autoantibodies and post-partum thyroiditis on the fetus and neonate
  283. Evidence for acute release of thyroid peroxidase during subtotal thyroidectomy
  284. Influence of interleukin 6 on the function of secondary cultures of human thyrocytes
  285. Thyroid function and autoimmune manifestations in insulin-dependent diabetes mellitus during and after pregnancy
  286. Thyroid function tests in patients with acquired immune deficiency syndrome and healthy HIV1-positive out-patients
  287. Interleukin-6 Is Not a Second Mediator of Interleukin-1 Induced Suppression of Thyroid Function in Cultured Human Thyrocytes
  288. Interleukin 6: A Pathogenic Factor in Autoimmune Thyroid Diseases?
  289. Thyroid Peroxidase and Thyroid Autoimmunity Report on the International Symposium on Thyroperoxidase and Thyroid Autoimmunity, held in Marseille (France), June 28–30, 1990
  290. Comparison Between Microsomal Antibodies by Immunofluorescence and Anti-TPO Antibodies in Healthy Individuals and Thyroid Autoimmune Diseases
  291. Endotoxins Do not Mimick the Effect of Interleukin-1 in Secondary Cultures of Human Thyroid Cells
  292. The Thyroid Function and Size in Healthy Man During 3 Weeks Treatment with β-Adrenoceptor-Antagonists
  293. Anti-Thyroid Peroxidase Antibodies in Thyroid Disorders and Non-Thyroid Autoimmune Diseases
  294. Thyroid size and function in healthy pregnant women with thyroid autoantibodies. Relation to development of postpartum thyroiditis
  295. Differential effects of interleukin 1  and 1  on cultured human and rat thyroid epithelial cells
  296. Anti-Thyroid Peroxidase Antibodies During Pregnancy and Postpartum. Relation to Postpartum Thyroiditis
  297. The variable intrafamiliar expressivity in Pendred's syndrome
  298. Characterization of the natural killer cell activity in Hashimoto's and Graves' diseases
  299. Serum thyroglobulin during the menstrual cycle, during pregnancy, and post partum
  300. FEATURES OF ENDOTHELIAL DYSFUNCTION IN EARLY DIABETIC NEPHROPATHY
  301. Suppressed Natural Killer Cell Activity in Patients with Euthyroid Graves' Ophthalmopathy
  302. Interleukin-1 affects the function of cultured human thyroid cells
  303. Pathogenic role of interleukin 1 and tumor necrosis factor in autoimmune endocrine diseases
  304. Lacking evidence for release of thyroid hormones from circulating thyroglobulin during subtotal thyroidectomy
  305. Thyroid function in patients with Pendred’s syndrome
  306. Thyroid stimulating antibodies in rheumatoid arthritis: an in vitro phenomenon
  307. The influence of interleukin-1 on the function of in vitro cultured human thyroid cells in monolayers
  308. Increased sympathetic tone in forearm subcutaneous tissue in primary hypothyroidism
  309. Thyroid function in patients with breast cancer
  310. IgG SUBCLASS DISTRIBUTION OF THYROID AUTOANTIBODIES: A ‘FINGERPRINT’ OF AN INDIVIDUAL'S RESPONSE TO THYROGLOBULIN AND THYROID MICROSOMAL ANTIGEN
  311. Cytokines in autoimmunity
  312. Serum thyroglobulin in chronic renal failure—effects of haemodialysis
  313. Natural Killer Cell Activity in Hashimoto, Graves’ Disease and Euthyroid Exophthalmos
  314. Serum thyroglobulin in chronic renal failure—effects of haemodialysis
  315. Serum Thyroid Autoantibodies in Patients with Breast Cancer
  316. Thyroid Autoantibodies in Thyroid Cancer
  317. Persistence of Autoimmune Reactions During Recovery of Subacute Thyroiditis
  318. The Influence of Interleukin-1 on The Function of Human Thyroid Cells
  319. Thyroid Stimulating Immunoglobulins without Evidence of in Vivo Thyroid Stimulation in Some Non-Thyroid Autoimmune Diseases
  320. SERUM THYROGLOBULIN CONCENTRATIONS IN INFANTS OF VARIOUS MATURITY
  321. Short-term betaadrenergic blockade decreases serum thyroglobulin in hyper- and euthyroid patients
  322. Autoreactive lymphocytes in thyroid disorders. Quantitation of anti-thyroglobulin antibody formation by a specific haemolytic plaque forming cell (PFC) assay
  323. Serum thyroglobulin concentration in nontoxic goiter and response to surgery with special reference to risk of goiter relapse
  324. Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo
  325. Humoral Autoimmune Manifestation in Subacute Thyroiditis
  326. INCREASED FREQUENCY OF GOITRE IN EPILEPTIC PATIENTS ON LONG-TERM PHENYTOIN OR CARBAMAZEPINE TREATMENT
  327. HIGH FREQUENCY OF GOITRE IN CIGARETTE SMOKERS
  328. An enzyme linked immunosorbent assay (ELISA) for measurement of human serum thyroglobulin. Evaluation of the influence of thyroglobulin auto-antibodies
  329. The differential diagnostic problems in unilateral euthyroid Graves' ophthalmopathy
  330. Heterogeneity of Autoimmune Thyroiditis
  331. Relationship between thyroid volume and serum thyroglobulin during long-term suppression with triiodothyronine in patients with diffuse non-toxic goitre
  332. Serum Thyroglobulin and Thyroglobulin Autoantibodies in Thyroid Diseases
  333. SERUM THYROGLOBULIN IN ACUTE AND CHRONIC LIVER DISEASE
  334. Circulating Immune Complexes in Hashimoto's Thyroiditis
  335. Discrepancy between Haemagglutination and Radioimmunological Techniques for Measurement of Serum Thyroglobulin Autoantibodies
  336. Thyroid-Stimulating Immunoglobulins in Hashimoto′s Thyroiditis Measured byRadioreceptor Assay and Adenylate Cyclase Stimulation and Their Relationship to HLA-D Alleles*
  337. Serum thyroglobulin and its autoantibody following subtotal thyroid resection of Graves' disease
  338. Serum thyroglobulin in patients undergoing subtotal thyroidectomy for toxic and nontoxic goiter
  339. Thyroid Stimulating Antibodies, Thyroglobulin Antibodies and Serum Proteins during Treatment of Graves? Disease with Radioiodine or Propylthouracil
  340. THE ACUTE CHANGES IN THYROID STIMULATING IMMUNOGLOBULINS, THYROGLOBULIN AND THYROGLOBULIN ANTIBODIES FOLLOWING SUBTOTAL THYROIDECTOMY
  341. A prospective study of the differential changes in serum thyroglobulin and its autoantibodies during propylthiouracil or radioiodine therapy of patients with Graves' disease
  342. Influence of Thyroglobulin on Basal and Stimulated Human Thyroid Adenylate Cyclase Activity*
  343. In vitro Characterization of Synthesized Thyroglobulin Immune Complexes (IC).
  344. Variability of plasma proteins according to molecular size. Long-term and short-term intra-individual variation
  345. Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects
  346. Circulating Immune Complexes and Complement-fixing Antibodies in Patients with Varicella-Zoster Infection: Relationship to Début of the Disease
  347. SEQUENTIAL CHANGES IN SERUM THYROGLOBULIN (Tg) AND ITS AUTOANTIBODIES (TgAb) FOLLOWING SUBTOTAL THYROIDECTOMY OF PATIENTS WITH PREOPERATIVELY DETECTABLE TgAb
  348. Falsely negative urinary leucocyte counts due to delayed examination
  349. Variations in Plasma Protein Concentrations in Individuals with Ulcerative Colitis: Analytical and Biological Factors
  350. SERUM THYROGLOBULIN IN PATIENTS WITH TOXIC AND NON-TOXIC GOITRES COMPARED TO SEX- AND AGE-MATCHED CONTROL SUBJECTS
  351. SEX AND AGE CORRELATED REFERENCE VALUES OF SERUM THYROGLOBULIN MEASURED BY A MODIFIED RADIOIMMUNOASSAY
  352. EFFECT OF CLOMIFENE ON THYROID FUNCTION IN NORMAL MEN
  353. THYROGLOBULIN OF VARYING MOLECULAR SIZES WITH DIFFERENT DISAPPEARANCE RATES IN PLASMA FOLLOWING SUBTOTAL THYROIDECTOMY
  354. Purification of human thyroglobulin for radioimmunoassay and testing by ultracentrifugal analysis and immunoelectrophoresis
  355. ADDITION OF MECHANICAL DEAD SPACE DURING I.P.P.B. WITH THE PREDICTED VITAL CAPACITY AS THE GUIDE
  356. Infusion Urography
  357. Infusion Urography